Phorbol 13-acetateCAS# 32752-29-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 32752-29-7 | SDF | Download SDF |
| PubChem ID | 499953 | Appearance | Powder |
| Formula | C22H30O7 | M.Wt | 406.47 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC1C(C2(C(C2(C)C)C3C1(C4C=C(C(=O)C4(CC(=C3)CO)O)C)O)OC(=O)C)O | ||
| Standard InChIKey | SDSVJYOOAPRSDA-RPCQODIISA-N | ||
| Standard InChI | InChI=1S/C22H30O7/c1-10-6-15-20(27,17(10)25)8-13(9-23)7-14-16-19(4,5)22(16,29-12(3)24)18(26)11(2)21(14,15)28/h6-7,11,14-16,18,23,26-28H,8-9H2,1-5H3/t11-,14+,15-,16-,18-,20-,21-,22-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Phorbol 13-acetate Dilution Calculator
Phorbol 13-acetate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4602 mL | 12.301 mL | 24.6021 mL | 49.2041 mL | 61.5052 mL |
| 5 mM | 0.492 mL | 2.4602 mL | 4.9204 mL | 9.8408 mL | 12.301 mL |
| 10 mM | 0.246 mL | 1.2301 mL | 2.4602 mL | 4.9204 mL | 6.1505 mL |
| 50 mM | 0.0492 mL | 0.246 mL | 0.492 mL | 0.9841 mL | 1.2301 mL |
| 100 mM | 0.0246 mL | 0.123 mL | 0.246 mL | 0.492 mL | 0.6151 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Heliosupine
Catalog No.:BCN1980
CAS No.:32728-78-2
- tcY-NH2
Catalog No.:BCC5770
CAS No.:327177-34-4
- Cyclohexanecarboxylic acid
Catalog No.:BCN3443
CAS No.:98-89-5
- VU 0285683
Catalog No.:BCC6154
CAS No.:327056-22-4
- TDZD-8
Catalog No.:BCC4258
CAS No.:327036-89-5
- TCS-PIM-1-4a
Catalog No.:BCC5461
CAS No.:327033-36-3
- Chlorogenic acid
Catalog No.:BCN5906
CAS No.:327-97-9
- H-Nle-OH
Catalog No.:BCC3295
CAS No.:327-57-1
- MHY1485
Catalog No.:BCC6404
CAS No.:326914-06-1
- Shz 1
Catalog No.:BCC6334
CAS No.:326886-05-9
- FAAH inhibitor 1
Catalog No.:BCC4254
CAS No.:326866-17-5
- Edpetiline
Catalog No.:BCN6771
CAS No.:32685-93-1
- Macrocarpal L
Catalog No.:BCN5248
CAS No.:327601-97-8
- BIO 5192
Catalog No.:BCC8002
CAS No.:327613-57-0
- Macrocarpal O
Catalog No.:BCN7371
CAS No.:327622-65-1
- Protopanaxatriol
Catalog No.:BCC9245
CAS No.:32773-56-1
- Labetalol HCl
Catalog No.:BCC5489
CAS No.:32780-64-6
- Panaxatriol
Catalog No.:BCN1081
CAS No.:32791-84-7
- Nomifensine
Catalog No.:BCC7226
CAS No.:32795-47-4
- H-D-Leu-OH
Catalog No.:BCC2975
CAS No.:328-38-1
- Ceranib 1
Catalog No.:BCC6186
CAS No.:328076-61-5
- Phortress
Catalog No.:BCC3901
CAS No.:328087-38-3
- Coniferyl alcohol
Catalog No.:BCN4651
CAS No.:32811-40-8
- (H-Cys-OMe)2.2HCl
Catalog No.:BCC2916
CAS No.:32854-09-4
Soy Phosphatidylglycerol Reduces Inflammation in a Contact Irritant Ear Edema Mouse Model In Vivo.[Pubmed:29695409]
J Pharmacol Exp Ther. 2018 Jul;366(1):1-8.
We have previously shown that phosphatidylglycerol (PG) regulates the function of keratinocytes, the predominant cells that compose the epidermis, inhibiting the proliferation of rapidly dividing keratinocytes. In particular, soy PG, a PG mixture with a high proportion of polyunsaturated fatty acids, is efficacious at inhibiting these proliferating keratinocytes. Psoriasis is a skin disorder characterized by hyperproliferation of keratinocytes and inflammation. Data in the lung suggest that PG in pulmonary surfactant inhibits inflammation. To investigate the possibility of using PG containing polyunsaturated fatty acids for the treatment of psoriasis, we examined the effect of soy PG on inflammation induced by the application of 12-O-tetradecanoylPhorbol 13-acetate (TPA), a contact irritant, to mouse ears in vivo. We monitored ear thickness and weight as a measure of ear edema, as well as CD45-positive immune cell infiltration. Our results indicate that soy PG when applied together with 1,25-dihydroxyvitamin D3 (vitamin D), an agent known to acutely disrupt the skin barrier, suppressed ear edema and inhibited the infiltration of CD45-positive immune cells. On the other hand, neither PG nor vitamin D alone was effective. The combination also decreased tumor necrosis factor-alpha (TNFalpha) levels. This result suggested the possibility that PG was not permeating the skin barrier efficiently. Therefore, in a further study we applied PG in a penetration-enhancing vehicle and found that it inhibited inflammation induced by the phorbol ester and decreased CD45-positive immune cell infiltration. Our results suggest the possibility of using soy PG as a topical treatment option for psoriasis.
